Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04264767 · ClinicalTrials.gov registry record
Characterization of Methylation Patterns in Cancer and Non-Cancer cfDNA
A clinical trial of Cancer and Solid Tumor, sponsored by Nucleix.
- Completed
- Registry status
- 800
- Enrollment target
- 3
- Study locations
NCT04264767: Completed study of Cancer and Solid Tumor, sponsored by Nucleix.
NCT04264767 is a study of Cancer and Solid Tumor that has completed, run by Nucleix. The registered enrollment target is 800 participants, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (77% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04264767, a study of Cancer and Solid Tumor, has completed, sponsored by Nucleix.
- COMPLETED
- Registry status
- 800 participants
- Enrollment target
- 3
- Study locations
Study Summary
Nucleix EpiCheck® tests analyzes the methylation pattern in a panel of DNA methylation biomarkers and determines whether this pattern is consistent with cancer under test or with non-cancer tissue. This study is being performed as part of the development process of the Pan Cancer EpiCheck test which includes the identification of different methylation profiles in various cancer types and healthy controls.
Primary Outcome
To collect blood and urine samples and clinical data in order to characterize methylation patterns that will discriminate cancer and normal (non-cancer) samples and the origin of cancer
Conditions Studied
Interventions
- PROCEDURE Blood collection
Study Locations (3)
California
- Los Angeles Hematology Oncology Medical Group - Wilson Terrace - Glendale
- Los Angeles Hematology Oncology Medical Group - Good Samaritan Medical Offices - Los Angeles
Other
- Sourasky Medical Center - Tel Aviv
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2019-04-17 |
| Est. Completion | 2021-01-30 |
What the finished NCT04264767 record still lists
NCT04264767 is an observational study that tracks outcomes without assigning an intervention. The registered 800 participants enrollment target is mid-sized for trials with a published cap, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (77% lower).
The record links to 3 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Blood collection is the first listed.
NCT04264767 reports a single indexed study location in California, Other.
Frequently Asked Questions
What is clinical trial NCT04264767 about?
NCT04264767 is a clinical study titled "Characterization of Methylation Patterns in Cancer and Non-Cancer cfDNA". Nucleix EpiCheck® tests analyzes the methylation pattern in a panel of DNA methylation biomarkers and determines whether this pattern is consistent with cancer under test or with non-cancer tissue. This study is being performed as part of the development process of the Pan Cancer EpiCheck test whic...
What is the current status of trial NCT04264767?
This trial is currently completed. The enrollment target is 800 participants. The study started on 2019-04-17. Estimated completion is 2021-01-30.
What conditions does trial NCT04264767 study?
This clinical trial studies the following conditions: Cancer, Solid Tumor, Hematologic Neoplasms.
What interventions are being tested in trial NCT04264767?
The interventions under investigation include: Blood collection (PROCEDURE).
Who is sponsoring clinical trial NCT04264767?
This trial is sponsored by Nucleix, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04264767 being conducted?
This trial has 3 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04264767's enrollment target sits among peer trials
800 94th of 615 higher than 521 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
Long-Term Follow-Up of Recipient of Gene Transfer Research
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00695214 · 800 participants · Phase 2
Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea
- NCT03048201 · 800 participants · NA
Physica System Total Knee Replacement Registry Study
- NCT03792659 · 800 participants
The EXPLORE MG Registry for Myasthenia Gravis
- NCT03819296 · 800 participants · Phase 1
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI